Compare Quest Diagnostics Inc (DGX) vs Google Inc (GOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Google Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Google Inc trades at $347.86 (market cap $4.24T). The key difference: Google Inc is far larger — about 166.4× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Google Inc for 137 Days on average.
| DGX | GOOG | |
|---|---|---|
Market Cap | $25.48B | $4.24T |
Volume | 941,866 | 13,937,902 |
Sector | Health | Media |
52-Week High | $247.45 | $399.06 |
52-Week Low | $173.49 | $237.49 |
Typical Hold Time | 56 Days | 137 Days |
Enterprise Value | $31.23B | $4.13T |
Dividend Yield | 1.49% | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
Alphabet (GOOG) trades at $344.86, down 0.72% today, with a bullish technical signal from moving averages and strong support near $342. The company reported robust Q2 2026 EPS of $9.11, beating expectations, with revenue growth accelerating to $402.84B in 2025. Analyst consensus is strongly bullish with an 87% buy rating and a $435.24 price target, though recent news highlights rising capital expenditures and potential free cash flow pressures.
Outlook remains positive driven by AI and cloud expansion, but risks include heightened spending, regulatory scrutiny, and class-action lawsuits. The stock's valuation at a P/E of 17.3 appears reasonable given high profitability margins, positioning it for long-term growth if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
